Want to see KR:069620 full AI Analyst Report?
Top Page
Daewoong Pharmaceutical Co., Ltd.
(069620)
Select Model
Select Model
Rating:61Neutral
Price Target:
$104,551
Action:N/A
Date:10/28/26
The score is driven primarily by mixed financial performance—strong recent profitability and growth, but ongoing negative free cash flow and higher leverage. Technicals are a meaningful drag due to a clear downtrend across key moving averages and negative MACD, despite oversold readings. Valuation provides support via a low P/E, helping offset the technical weakness.
Positive Factors
Revenue and Margin Growth
Sustained revenue expansion alongside gross margins above 50% and a sharp recovery in net margin indicates stronger recent operating performance. This supports reinvestment in pharmaceutical development, expands the earnings base, and may improve the company’s ability to compete across domestic and international markets.
Negative Factors
Rising Leverage
Debt has increased materially faster than the earlier balance-sheet base, leaving borrowings at roughly 0.87 times equity in the latest period. This reduces financial flexibility if profitability weakens, increases the importance of successful cash conversion, and can constrain investment or capital-allocation choices.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Margin Growth
Sustained revenue expansion alongside gross margins above 50% and a sharp recovery in net margin indicates stronger recent operating performance. This supports reinvestment in pharmaceutical development, expands the earnings base, and may improve the company’s ability to compete across domestic and international markets.
Read all positive factors
Daewoong Pharmaceutical Co., Ltd. (069620) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩1.15T
Dividend Yield0.6%
Average Volume (3M)15.47K
Price to Earnings (P/E)5.9
Beta (1Y)0.10
Revenue Growth9.87%
EPS Growth160.28%
CountryKR
Employees1,794
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)16988.79
Shares Outstanding11,586,575
10 Day Avg. Volume18,329
30 Day Avg. Volume15,475
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.27
P/FCF Ratio-47.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)17,377.79
Revenue Forecast (FY)₩1.62T
Daewoong Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1945 and headquartered in Seoul, South Korea, Daewoong Pharmaceutical Co., Ltd. is a global entity dedicated to the research, production, and international distribution of a diverse range of pharmaceutical products. Its extensive po...
Daewoong Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
67
Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.64T | 1.57T | 1.42T | 1.38T | 1.28T | 1.15T |
| Gross Profit | 843.59B | 812.85B | 734.17B | 687.11B | 638.96B | 544.75B |
| EBITDA | 256.41B | 245.78B | 112.52B | 164.91B | 86.80B | 129.61B |
| Net Income | 195.47B | 195.86B | 24.73B | 121.74B | 42.24B | 24.51B |
Balance Sheet | ||||||
| Total Assets | 2.54T | 2.36T | 1.98T | 1.77T | 1.56T | 1.42T |
| Cash, Cash Equivalents and Short-Term Investments | 158.42B | 172.80B | 116.35B | 137.68B | 140.65B | 173.73B |
| Total Debt | 925.02B | 829.39B | 649.25B | 469.69B | 446.71B | 445.70B |
| Total Liabilities | 1.35T | 1.23T | 1.05T | 858.03B | 822.12B | 712.77B |
| Stockholders Equity | 1.06T | 1.01T | 794.64B | 767.30B | 608.02B | 573.57B |
Cash Flow | ||||||
| Free Cash Flow | -117.44B | -42.33B | -177.51B | 26.67B | 4.91B | -34.80B |
| Operating Cash Flow | 162.15B | 149.21B | 51.49B | 136.01B | 118.21B | 39.99B |
| Investing Cash Flow | -345.17B | -247.36B | -265.45B | -165.62B | -106.87B | -87.68B |
| Financing Cash Flow | 172.80B | 164.69B | 200.62B | 39.22B | 15.52B | 50.22B |
Daewoong Pharmaceutical Co., Ltd. Technical Analysis
Negative
―
Price Trends
112538.00
Negative
117612.00
Negative
137954.50
Negative
Market Momentum
-3240.35
Positive
34.72
Neutral
5.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:069620, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 105545.00, equal to the 50-day MA of 112538.00, and equal to the 200-day MA of 137954.50, indicating a bearish trend. The MACD of -3240.35 indicates Positive momentum. The RSI at 34.72 is Neutral, neither overbought nor oversold. The STOCH value of 5.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:069620.
Daewoong Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩560.29B | 5.53 | ― | 2.80% | 10.50% | 96.29% | |
61 Neutral | ₩1.15T | 5.90 | ― | 0.60% | 9.87% | 160.28% | |
59 Neutral | ₩169.24B | 2.61 | ― | 3.94% | 1.43% | 106.56% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₩1.61T | 130.86 | ― | 0.42% | 13.88% | 29.24% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
46 Neutral | ₩332.73B | -56.26 | ― | 2.01% | 15.38% | ― |
* General Sector Average
KR:069620
Daewoong Pharmaceutical Co., Ltd.
99,900.00
-36,329.16
-26.67%
KR:001060
JW Pharmaceutical Corporation
23,200.00
533.84
2.36%
KR:001630
Chong Kun Dang Holdings Co., Ltd.
35,550.00
-8,380.59
-19.08%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
177.39
4.97%
KR:068760
Celltrion Pharm Inc.
37,100.00
-24,465.13
-39.74%
KR:170900
Dong-A ST Co., Ltd.
34,900.00
-9,625.21
-21.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.